Neil Desai, PhD, is the Founder, CEO and Chairman of Aanastra, Inc., and cofounder of Divincell SAS, companies that are pioneering novel peptide-based RNA therapeutic drug delivery for the treatment of cancer and genetic diseases. Dr. Desai is also the founder, Executive Chairman and former CEO (2014-Dec 2022) of Aadi Bioscience, which he steered to the public market (AADI: Nasdaq) in August 2021, and to the approval as well as commercialization of its flagship drug FYARRO, the first FDA approved therapy for advanced malignant perivascular epithelioid cell tumor (PEComa). He was responsible for building Aadi from a single person to over 80 employees and raised multiple financing rounds (private and public) totalling over $265M.